Mersana is a biopharmaceutical company specializing in the discovery and development of antibody-drug conjugate (ADC) therapies to treat patients fighting cancer. Leveraging decades of industry learnings, we have developed proprietary and highly differentiated ADC platforms and expertise to rapidly design and test novel ADCs and identify those with optimal efficacy, safety and tolerability. Using this strategy, we are building a robust pipeline of ADC candidates with the potential to make a life-changing difference for people living with cancer. Our lead candidate, upifitamab rilsodotin (UpRi), is a first-in-class Dolaflexin ADC targeting NaPi2b and is being studied in UPLIFT, a single-arm registration study, in patients with platinum-resistant ovarian cancer, as well as in UPGRADE, a Phase 1 umbrella study, combining UpRi with other ovarian cancer therapies. XMT-1592, our second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana’s customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Company’s early-stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING-agonist ADC developed using the Company’s Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2 (HER2).
September 10, 2021 at 8:00 AM EDT
Mersana UpRi Clinical Development Strategy and Interim Data from the Ovarian Cancer Expansion Cohort of the Phase I Study
November 9, 2021 at 8:00 AM EST
Mersana Third Quarter 2021 Earnings Call
December 1, 2021 at 2:40 PM EST